Celgene: Cancer Biotech For Accelerated Stock Growth

Mon, 06/11/2012 - 13:16 EDT - Seeking Alpha

By David Zanoni:If you're looking for an established biotech company with a number of FDA approved drugs already on the market, then Celgene Corporation (CELG) is one to consider. This $28.6 billion large-cap company has five established drugs for the treatment of various cancers currently being marketed. This takes the guesswork out of investing as compared to younger biotech companies which don't yet have any FDA approved drugs on the market.Celgene's five FDA approved drugs include: Revlimid for the treatment of multiple myeloma and MDS; Vidaza for the treatment of MDS and acute myeloid leukemia; Thalomid for the treatment of multiple myeloma; Abraxane for the treatment of metastatic breast cancer; and Isodax for the treatment of T-cell lymphoma. These are the drugs that have contributed to Celgene's 15% growth in revenue for Q1 2012.The company's extensive pipeline is another area of strength. Celgene has over 20 new compounds in theComplete Story »

Original article
Login or register to post comments

Celgene Offers Stable Revenue And A Solid Product Portfolio
ByEquity Watch: Investment Thesis Celgene Corporation (CELG) is a biopharmaceutical which engages in the discovery and commercialization of therapies for the treatment of cancer and immune-inflammatory diseases. Its primary marketed products at the moment include: Thalomid, Revlimid, Vidaza and Abraxane. The first three products are used in the treatment of blood cancer.
Celgene Expands Its Oncology Focus
The Burrill Report submits: by Marie Daghlian
Survey Of The Pancreatic Cancer Drug Market With Celgene's Abraxane In Focus
By Ed Liston: This year, a number of cancer drugs have received the FDA approval. In October 2012, the FDA approved Abraxane for the treatment of non-small cell lung cancer. Abraxane is marketed by Celgene (CELG).
Celgene Could Be Turbocharged With 2 Blockbusters: Revlimid And Apremilast
ByNick Chiu:Celgene (CELG) is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. Celgene's current main products include Revlimid, Abraxane, Vidaza, and Thalomid.
What To Expect For The Future Of Celgene
By David Zanoni: One company that is excelling in the biotech industry is Celgene Corporation (CELG). The company is a leader in cancer and immune-inflammatory treatments. Revenue increased 16% for Q2 2012. This growth was considered high-quality growth as 14 of those 16 percentage points came from volume increases for its products. Earnings per share increased 37% in the second quarter.
Celgene Prelims Look Upbeat
Zacks.com submits: Yesterday, Celgene Corporation (CELG) announced preliminary (unaudited) results for the fourth quarter of fiscal 2009 (ended December 31). The company earned 62 cents per share, beating the Zacks Consensus Estimate by 5 cents.
Celgene's Star Drug Revlimid And Its Competitors
By Peter Geschek:Few biotech firms can match Celgene's (CELG) recent success: its shares have more than doubled in the past two years. The success can largely be credited to one drug: Revlimid, one of the most successful cancer therapies ever developed.
Celgene And The Race To Cure Multiple Myeloma
By Peter Geschek: Pomalyst In February the FDA approved Pomalyst (pomalidomide) developed by Celgene (CELG) for the treatment of patients with multiple myeloma whose disease progressed after being treated with other cancer drugs, like Celgene's Revlimid or Johnson & Johnson/Takeda's Velcade.
Celgene Earnings: What To Watch For
By Wall Street Trading: By Joseph Morrison Firm Overview
Is There a Value Opportunity in Celgene's Contingent Value Rights?
Frank Voisin submits: Lung Cancer is the number one cancer killer globally, claiming approximately 1.2 million lives annually. Non-Small Cell Lung Cancer (NSCLC) is the most common, accounting for 85% of lung cancers. Abraxis Bioscience was a biopharmaceutical company that was recently purchased by Celgene Corp. (CELG).

Main menu

Secondary menu

Celgene: Cancer Biotech For Accelerated Stock Growth

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu